PDA: Benefits, Dosage & FDA Status
Pentadeca Arginate (PDA)
A 15-amino-acid arginate analog developed as a more stable, sometimes more bioavailable alternative to BPC-157. Limited published research; popular among compounding pharmacies in 2025–2026.
FDA Status
Not FDA-approved — newer compounded analog of BPC-157
Typical Dose
200–500 mcg daily (subcutaneous)
Evidence Grade
C+Preclinical evidence + anecdotal clinical use
Half-Life
~6 hours (estimated)
Routes of Administration
subcutaneous, oral
First Synthesized
2024
Clinics Indexed
41 providers have offered PDA in our tracked directory.
Mechanism of Action
Arginate-stabilized analog of BPC-157 with proposed similar VEGF/angiogenic and tissue-repair effects.
Key Reported Benefits
- ✓Tissue repair
- ✓Anti-inflammation
- ✓Potentially better stability than BPC-157
Benefits listed reflect commonly reported effects from clinical trials and practitioner use. Individual response varies. Evidence-grade C+ indicates preclinical evidence + anecdotal clinical use.
Reported Side Effects
- •Limited published safety data
- •Injection-site reactions
Contraindications
- ⚠Active malignancy
- ⚠Pregnancy
Commonly Stacked With
Regulatory & Safety Context
FDA status: Not FDA-approved — newer compounded analog of BPC-157
This page is for educational purposes only and does not constitute medical advice. Peptide use outside of an FDA-approved indication should be discussed with a licensed medical professional. Source quality, cold-chain storage, and injection hygiene all materially affect safety outcomes.
See state-by-state legality: US peptide legality by state →
Related Peptides
TB-500
BA synthetic fragment of thymosin beta-4 that promotes cell migration, blood vessel formation, and tissue repair. Often stacked with BPC-157 as the 'Wolverine Stack.'
BPC-157
B+A 15-amino-acid peptide derived from gastric juice. The most popular recovery peptide with 100+ preclinical studies showing accelerated healing of tendons, ligaments, muscle, gut lining, and nerves.
CJC-1295 (no DAC)
BA growth hormone releasing hormone (GHRH) analog most commonly stacked with Ipamorelin to stimulate natural GH pulsatile release without disrupting the hypothalamic axis.
Hexarelin
BThe strongest GH-releasing hexapeptide and one of the few peptides with documented direct cardiac benefits in animal models. Tachyphylaxis (diminished response over time) limits long-term use.
Thymosin Alpha-1
AA 28-amino-acid thymic peptide that matures and modulates T-cells. Used internationally as an adjunct in hepatitis, sepsis, and immune-compromised cancer care.
KPV
C+The C-terminal tripeptide of α-MSH with documented anti-inflammatory activity in IBD and dermatitis preclinical models. Frequently delivered orally and topically.